Related Experiment Videos
Constructing a database of individual clinical trials for longitudinal analysis.
Christopher H Schmid1, Marcia Landa, Tazeen H Jafar
1Biostatistics Research Center, Division of Clinical Care Research, Department of Medicine, New England Medical Center Box 63, 750 Washington Street, Boston, MA 02111, USA. cschmid@lifespan.org
Controlled Clinical Trials
|May 22, 2003
Summary
Combining individual patient data from multiple trials on angiotensin-converting enzyme (ACE) inhibitors for kidney disease is complex but highly informative. This approach reveals how patient factors influence treatment effectiveness, aiding personalized medicine strategies.
Area of Science:
- Nephrology
- Clinical Pharmacology
- Biostatistics
Background:
- Individual patient data (IPD) analysis is crucial for understanding patient-specific factors influencing treatment effects.
- Meta-analyses of group data provide population-level insights but may obscure individual variability.
- Previous meta-analyses suggested angiotensin-converting enzyme (ACE) inhibitors slow renal disease progression.
Purpose of the Study:
- To confirm the efficacy of ACE inhibitors in slowing nondiabetic renal disease progression using IPD.
- To determine if patient or study characteristics modify the beneficial effects of ACE inhibitors.
- To investigate if blood pressure and urine protein levels mediate the effects of ACE inhibitors.
Main Methods:
- Combined individual patient data from 11 randomized controlled trials involving 1946 subjects.
- Standardized a complex, multi-lingual, multi-format database of over 60,000 longitudinal records over 4 years.
- Overcame challenges with inconsistent protocols, data definitions, missing data, and variable formats.
Main Results:
- Confirmed the efficacy of ACE inhibitors in slowing renal disease progression.
- Demonstrated the feasibility and informativeness of combining IPD from diverse trials.
- Found IPD analysis more informative than investigator-abstracted data.
Conclusions:
- Combining IPD from multiple trials, despite complexity, yields highly informative results for personalized treatment strategies.
- Funding agencies should support collaborative efforts for IPD pooling.
- ACE inhibitors are effective in slowing nondiabetic renal disease progression.